Inari Medical announces first patient enrolment in PEERLESS II randomised controlled trial
Inari Medical has announced the first patient enrolment in PEERLESS II. This prospective, global, multicentre randomised controlled trial (RCT) compares the outcomes of intermediate-risk...
First patient enrolled in STORM-PE RCT evaluating Penumbra’s Lightning Flash for treatment of acute...
Penumbra today announced that the first patient has been enrolled in STORM-PE, a prospective, multicentre, randomised controlled trial (RCT) evaluating anticoagulation alone versus anticoagulation...
Two-year BIOPACT randomised controlled trial analysis demonstrates “persistent excellence” for low-profile Passeo-18 Lux DCB
Biotronik has announced the presentation of two-year results from the investigator-initiated BIOPACT randomised controlled trial (RCT) by principal investigator Koen Deloose (AZ Sint-Blasius Hospital,...
Inari Medical completes LimFlow acquisition for CLTI treatment
Inari Medical has announced that it has completed its acquisition of chronic limb-threatening ischaemia (CLTI) treatment maker LimFlow.
The Irvine, California–based company earlier this month...
